Samsung BioLogics signs manufacturing partnership with Roche

Published: 25-Oct-2013
Manufacturing Pharmaceutical

Will manufacture biologic medicines for Roche at the Incheon, South Korea plants


South Korean contract manufacturer Samsung BioLogics has signed a manufacturing agreement with F. Hoffmann-La Roche under which Samsung will manufacture Roche's proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction.

Terms of the agreement have not been disclosed, including financial terms and products to be manufactured.

'We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in-class manufacturing services with the highest global quality standards,' said Tae-Han Kim, President and CEO of Samsung BioLogics.

'This collaboration with the world's largest biotech company is an important milestone for Samsung as it validates our long term strategy of becoming a leader in biopharmaceutical manufacturing.'

  • Companies:
  • Samsung
  • Roche Group
See more

You may also like

Regulatory

Roche's breast cancer combination therapy Itovebi bags FDA approval

Read more
Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  4. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Regulatory

Roche's breast cancer combination therapy Itovebi bags FDA approval

Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Regulatory

Roche receives approval for PiaSky to treat patients with PNH in Europe

The subcutaneous C5 inhibitor stops the patients from having to attend the clinic to receive IV infusions for PNH management
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Manufacturing

Immersive training programme implemented at Samsung Bioepis

Virtual-reality simulation education platform for the pharmaceutical and biotech industries has expanded its reach into Asia, most recently in South Korea
Manufacturing

Samsung Biologics first annual Sustainability Report

In the report, the company states its plans to build an eco-friendly business environment, supported by recently awarded ISO Certifications
Manufacturing

Samsung Bioepis opens Korea HQ for biologics

The building was completed in December 2020
Subscribe now